[go: up one dir, main page]

FI916077A0 - Ej glykosylerade proteiner som aer analoga med humant interleukin 3. - Google Patents

Ej glykosylerade proteiner som aer analoga med humant interleukin 3.

Info

Publication number
FI916077A0
FI916077A0 FI916077A FI916077A FI916077A0 FI 916077 A0 FI916077 A0 FI 916077A0 FI 916077 A FI916077 A FI 916077A FI 916077 A FI916077 A FI 916077A FI 916077 A0 FI916077 A0 FI 916077A0
Authority
FI
Finland
Prior art keywords
glycosylerade
proteiner
humant
analoga
interleukin
Prior art date
Application number
FI916077A
Other languages
English (en)
Other versions
FI916077A7 (fi
Inventor
David L Urdal
Helmut Sassenfeld
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of FI916077A7 publication Critical patent/FI916077A7/fi
Publication of FI916077A0 publication Critical patent/FI916077A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/823—Lower fungi, e.g. mold
    • Y10S530/824—Yeasts
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI916077A 1989-06-30 1990-06-13 Ej glykosylerade proteiner som aer analoga med humant interleukin 3. FI916077A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/374,667 US5128450A (en) 1989-06-30 1989-06-30 Nonglycosylated human interleukin-3 analog proteins
PCT/US1990/003345 WO1991000350A1 (en) 1989-06-30 1990-06-13 Nonglycosylated human interleukin-3 analog proteins

Publications (2)

Publication Number Publication Date
FI916077A7 FI916077A7 (fi) 1991-12-20
FI916077A0 true FI916077A0 (fi) 1991-12-20

Family

ID=23477728

Family Applications (1)

Application Number Title Priority Date Filing Date
FI916077A FI916077A0 (fi) 1989-06-30 1990-06-13 Ej glykosylerade proteiner som aer analoga med humant interleukin 3.

Country Status (12)

Country Link
US (1) US5128450A (fi)
EP (1) EP0482013B1 (fi)
JP (1) JPH04506342A (fi)
AT (1) ATE138099T1 (fi)
AU (1) AU630207B2 (fi)
CA (1) CA2033182A1 (fi)
DE (1) DE69027031T2 (fi)
DK (1) DK0482013T3 (fi)
ES (1) ES2090135T3 (fi)
FI (1) FI916077A0 (fi)
NO (1) NO301482B1 (fi)
WO (1) WO1991000350A1 (fi)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5328988A (en) * 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US5705362A (en) * 1992-05-25 1998-01-06 Gist-Brocades, N.V. Modified signal sequences
US5463029A (en) * 1992-11-23 1995-10-31 Immunex Corporation Purification of fusion proteins comprising GM-CSF and IL-3
US6361976B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
US6153183A (en) * 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US6403076B1 (en) 1992-11-24 2002-06-11 S. Christopher Bauer Compositions for increasing hematopoiesis with interleukin-3 mutants
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
DE69332908T2 (de) * 1992-11-24 2003-12-24 G.D. Searle & Co., Chicago Interleukin-3 (il-3)-polypeptide mith mehreren mutationen
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
AU699913B2 (en) * 1993-11-10 1998-12-17 Henry M. Jackson Foundation For The Advancement Of Military Medicine Compositions and method for stimulating antibody release by B lymphocytes
US6017523A (en) * 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
DE60036915T2 (de) 1999-01-13 2008-08-07 Alchemia Oncology Pty Ltd., Hawthorn Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
EP2135611A1 (en) 2001-03-01 2009-12-23 Hollis-Eden Pharmaceuticals Inc. Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
JP2005505540A (ja) * 2001-08-27 2005-02-24 メディテック　リサーチ　リミテッド 改善された治療プロトコール
JP4212827B2 (ja) * 2002-05-16 2009-01-21 シスメックス株式会社 骨髄液有核細胞自動分析方法
US20040138187A1 (en) 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
JP2008527981A (ja) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド 治療目的および診断目的のためにパラメーターにより選択されたｇｍ−ｃｓｆ、ｉｌ−３、ｉｌ−４、ｉｌ−５、ならびにそのキメラ
AU2006274509B2 (en) * 2005-07-27 2012-01-19 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
CN101287475B (zh) * 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途
JP5628544B2 (ja) * 2010-04-07 2014-11-19 株式会社豊田中央研究所 クロストリジウム・サーモセラム由来のタンパク質複合体を構築するためのタンパク質及びその利用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
US4877729A (en) * 1986-07-14 1989-10-31 Genetics Institute, Inc. Recombinant DNA encoding novel family of primate hematopoietic growth factors
EP0275598B1 (en) * 1986-12-16 1998-01-07 Gist-Brocades N.V. Molecular cloning and expression of human IL-3
ES2113338T3 (es) * 1986-12-16 1998-05-01 Gist Brocades Nv Clonado molecular y expresion de il-3 humano.
WO1988005469A1 (en) * 1987-01-20 1988-07-28 Immunex Corporation Human interleukin-3 proteins
OA09736A (en) * 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".
AU3864089A (en) * 1988-07-20 1990-02-19 Immunex Corporation Nonglycosylated human interleukin-3 compositions

Also Published As

Publication number Publication date
US5128450A (en) 1992-07-07
NO915116L (no) 1992-02-28
NO301482B1 (no) 1997-11-03
DK0482013T3 (da) 1996-06-03
ATE138099T1 (de) 1996-06-15
JPH04506342A (ja) 1992-11-05
DE69027031T2 (de) 1996-12-19
NO915116D0 (no) 1991-12-27
DE69027031D1 (de) 1996-06-20
ES2090135T3 (es) 1996-10-16
FI916077A7 (fi) 1991-12-20
AU5821690A (en) 1991-01-17
EP0482013A1 (en) 1992-04-29
EP0482013B1 (en) 1996-05-15
AU630207B2 (en) 1992-10-22
WO1991000350A1 (en) 1991-01-10
CA2033182A1 (en) 1990-12-31

Similar Documents

Publication Publication Date Title
FI916077A0 (fi) Ej glykosylerade proteiner som aer analoga med humant interleukin 3.
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
ATE380037T1 (de) Verfaheren zur durch rekombinante adeno- assoziierte virus-gerichtete gentherapie
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
AU6701890A (en) Process for the production of biologically active protein
YU174490A (sh) Novi estri tienil-karboksilne kiseline sa aminoalkoholima, njihova kvaterna jedinjenja kao i pripremanje i primena tih jedinjenja
DK581185A (da) Farmaceutisk praeparat indeholdende 13-cis-a-vitaminsyre
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
EP1440980A3 (en) Peptide analogs of human myelin basic protein
PT89534A (pt) Processo para a preparacao de composicoes farmaceuticas anticoagulantes contendo como ingrediente activo proteina c ou proteina c activada combinada com heparina
MY101784A (en) Novel pharmacological compounds
TW362973B (en) Use of 2-anino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a composition having an antidepressant activity
DE69024104D1 (de) Polypeptide und Polypeptidanaloge mit inhibitorischer Aktivität gegenüber menschlicher Elastase
ID820B (id) Turunan benzisotiazolinon-1-dioksid sebagai penghambat elastase
AU2308992A (en) Cysteine depleted il-6 muteins
DE69636052D1 (de) Mpl-liganden analoga
ATE67783T1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
KR910005886A (ko) 안정화 백혈구 인터페론
EP0209843A3 (en) Benzylpiperazine compound, preparation thereof, pharmaceutical composition, and use
IE871358L (en) Interferon for carcinoma
EP0820771A3 (de) Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und eine Magnesiumverbindung enthält
SE8704240D0 (sv) Analgesic preparations
ES2073063T3 (es) Formulaciones galenicas acuosas de eritropoyetina y su uso.
JPS6429A (en) Antiviral agent
SE8704049D0 (sv) Novel pharmacological compounds

Legal Events

Date Code Title Description
FD Application lapsed